This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
The New England journal of medicine · 2023
Latest funding
- $2,000,000
Allogeneic regulatory T cell therapy to prevent graft versus host disease
CIHR · 2024 · Co-investigator
- $20,000
Allogeneic regulatory T cell therapy to prevent chronic graft versus host disease
CIHR · 2023 · Principal investigator
1 publications.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL, ZUMA-7 Investigators, Kite Members
Allogeneic regulatory T cell therapy to prevent graft versus host disease
Principal investigators: Levings, Megan K; Schultz, Kirk R; Ahmad, Imran; Dijke, Ilona E; Hay, Kevin A; Lad, Deepesh P; West, Lori J
Keywords: Cell Therapy; Graft Versus Host Disease; Regulatory T Cells; Tolerance; Transplantation
Allogeneic regulatory T cell therapy to prevent chronic graft versus host disease
Principal investigators: Levings, Megan K; Delisle, Jean-Sébastien; Ahmad, Imran; Dijke, Ilona E; Elsawy, Mahmoud E; Hay, Kevin A; Kekre, Natasha; Szwajcer, David; West, Lori J
Keywords: Cell Therapy; Graft Versus Host Disease; Regulatory T Cells; Tolerance; Transplantation
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.